This research report evaluates the SC291 hypoimmune (HIP) CD19 CAR T cell product, an allogeneic therapy engineered to treat cancers and autoimmune diseases without triggering patient rejection. By utilizing CRISPR-Cas editing to remove HLA markers and overexpress CD47, these specialized cells successfully bypassed both innate and adaptive immune responses in clinical trial participants. The study observed that while patients' immune systems attacked partially edited cells, the fully edited HIP CAR T cells remained protected and functionally active. Furthermore, researchers discovered that a lack of donor-specific antibodies against unedited cells serves as a reliable indicator for deep tissue B cell depletion. These findings confirm the HIP platform's ability to evade allorejection, offering a promising path toward universal, off-the-shelf cell therapies. Ultimately, the data support the reliability of this engineering concept in overcoming the significant immunological barriers that typically limit allogeneic treatments.

References:

• Hu X, Beauchesne P, Wang C, et al. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease[J]. Cell Stem Cell, 2025, 32(9): 1356-1368. e4.